A5009438948- Pancreatic and Hepatic Oncology Research
- Gastric Cancer Management and Outcomes
- Colorectal Cancer Treatments and Studies
- Cholangiocarcinoma and Gallbladder Cancer Studies
- Renal cell carcinoma treatment
- Cancer Genomics and Diagnostics
- Gallbladder and Bile Duct Disorders
- Gastrointestinal Tumor Research and Treatment
- Lung Cancer Treatments and Mutations
- Barrier Structure and Function Studies
- Hepatocellular Carcinoma Treatment and Prognosis
- Metastasis and carcinoma case studies
- Cancer, Hypoxia, and Metabolism
- Multiple and Secondary Primary Cancers
- Cancer Immunotherapy and Biomarkers
- Radiomics and Machine Learning in Medical Imaging
- Neutropenia and Cancer Infections
- Cancer Mechanisms and Therapy
- Colorectal Cancer Surgical Treatments
- Advanced Breast Cancer Therapies
- Cancer Cells and Metastasis
- Colorectal and Anal Carcinomas
- Cancer Treatment and Pharmacology
- Neuroendocrine Tumor Research Advances
- Biliary and Gastrointestinal Fistulas
Russian Cancer Research Center NN Blokhin
2013-2025
Ministry of Health of the Russian Federation
2020-2025
Tver State Medical University
2020-2024
Sechenov University
2018
All-Russian Scientific Research Institute of Irrigation and Agricultural Water Supply "Raduga"
2016
Cell-free DNA from dying cells recently has been discovered in human blood plasma. In experiments performed on animals and humans, we examined whether this cell-free can cross the kidney barrier be used as a diagnostic tool.Mice received subcutaneous injections of either Raji or purified (32)P-labeled DNA. was isolated urine analyzed by measurement radioactivity, agarose gel electrophoresis, PCR. permeability to polymeric assessed detection sequences that were different an organism bulk...
The selective MEK1/2 inhibitor pimasertib has shown anti‐tumour activity in a pancreatic tumour model. This phase I/II, two‐part trial was conducted patients with metastatic adenocarcinoma (mPaCa) (NCT01016483). In the I part, oral given once daily discontinuously (5 days on/2 off treatment) or twice continuously ( n = 53) combined weekly gemcitabine (1,000 mg/m 2 ) 28‐day cycles to identify recommended II dose (RP2D) of pimasertib. were randomised placebo plus 88) investigate...
4007 Background: Hypoxia in PDAC is associated with disease progression and poor prognosis. Evo a hypoxia-activated prodrug of Br-IPM that preferentially activated under hypoxic conditions. The addition to Gem significantly improved PFS randomized phase II trial advanced (NCT01144455). Methods: MAESTRO was an international, randomized, double-blind, placebo-controlled III Evo/Gem vs Placebo (Pbo)/Gem pts locally unresectable or metastatic (NCT01746979). 340 mg/m2 matched Pbo 1,000 were...
LBA4001 Background: Claudin18.2 (CLDN18.2) is a tight junction protein expressed by several cancers including gastric and GEJ adenocarcinoma. IMAB362 chimeric monoclonal antibody that mediates specific killing of CLDN18.2-positive cancer cells activation immune effector mechanisms. has demonstrated single-agent activity was safe tolerable in patients (pts) with pretreated cancer. Methods: Pts advanced/recurrent were centrally evaluated for CLDN18.2 expression IHC (validated CLAUDETECT18.2...
Objective. To identify prognostic factors and role of preoperative therapy for resectable intrahepatic cholangiocarcinoma (IHCC). Material methods. We analyzed the results surgical combined treatment IHCC between 1999 2023. Immediate long-term outcomes were evaluated depending on negative additional therapy. Results. The study included 195 patients. Postoperative complications grade ≥III observed in 35 (17.9%) case. Mortality rate was 3.1% (n=6). Thirty-eight patients (19.5%) underwent...
Background . Pancreatic cancer (PC) has long been a disease with limited treatment options, where the foundation of therapy was primarily based on cytostatics. However, advent first KRAS G12C inhibitors, new prospects have emerged for advanced PC, highlighting importance studying mutations, which occur in 80–95 % cases. In this context, it is relevant to analyze frequency various mutations among Russian population patients could help personalize further diagnostics and therapy. Aim. To study...
193 Background: Pancreatic ductal adenocarcinoma (PDAC) is invariably diagnosed at an advanced stage and has poor clinical outcome. Hypoxia a significant prognostic factor in PDAC progression associated with prognosis. Evofosfamide (Evo, previously known as TH-302) hypoxia-activated prodrug of bromo-isophosphoramide mustard (Br-IPM) that preferentially activated under hypoxic conditions. The addition Evo to gemcitabine (Gem) significantly improved progression-free survival (PFS) randomized...
344 Background: In metastatic pancreatic cancer (mPaCa), KRAS mutations lead to constitutive activation of the MAPK pathway in vast majority cases. Pimasertib (Pim) is a selective, non-competitive MEK 1/2 inhibitor with potent antitumor activity preclinical models activation. Methods: Following phase I, dose-finding part trial, 88 patients (pts) mPaCa were randomized 1:1 receive Pim 60 mg BID (A, 44 pts) or placebo (B, combination weekly gemcitabine (Gem) 1000 mg/m 2 (7 8 wks cycle 1, then 3...
16 Background: Physiologically, the tight junction protein CLDN18.2 is present only in gastric mucosa. Upon malignant transformation, epitopes are exposed on cell surface and accessible to targeted therapy. Zolbetuximab (formerly IMAB362) a chimeric mAb that mediates specific killing of CLDN18.2+ cancer cells through immune effector mechanisms; single-agent activity has been reported G/GEJ cancer. Methods: Patients (pts) with advanced HER2-negative (HER–) expression ≥ 2+ staining intensity...
LBA4001 The full, final text of this abstract will be available at abstracts.asco.org 7:30 AM (EDT) on Sunday, June 5, 2016, and in the Annual Meeting Proceedings online supplement to 20, issue Journal Clinical Oncology. Onsite Meeting, printed Monday edition ASCO Daily News.
This multicenter, randomized trial compared overall response rate between pemetrexed plus irinotecan (ALIRI) and leucovorin-modulated 5-fluorouracil (FOLFIRI) in patients with advanced colorectal cancer. Secondary objectives included progression-free survival, duration of response, toxicities, biomarkers.ALIRI received 500 mg/m(2) 350 vitamin supplementation on day 1 each 21-day cycle. FOLFIRI 180 days 1, 15, 29; 2, 16, 29, 30, leucovorin 200 mg/m(2), bolus 400 600 as 22-hour infusion.Of 132...
4038 Background: Claudin 18.2 (CLDN18.2), a gastric mucosa tight junction protein, is aberrantly expressed in various cancers. In the FAST Phase 2 trial (NCT01630083), IMAB362, an anti-CLDN18.2 monoclonal antibody, administered combination with EOX chemotherapy, prolonged survival compared to alone patients advanced/recurrent gastric, gastroesophageal (GEJ), and esophageal cancers ineligible for trastuzumab. The aim of present analysis was assess tumor CLDN18.2 expression co-expression HER2...
Pancreatic cancer is an aggressive disease with extremely unfavorable prognosis. The only effective method of treatment for this chemotherapy. introduction combined chemotherapy regimens and the development molecular oncology in recent years have changed approaches to tumor. This review presents current literature data, as well data from N. Blokhin National Medical Research Center Oncology, concerning modern aspects metastatic pancreatic cancer.
.
Due to the gain in average life expectancy developed countries there is increased incidence rate of malignant neoplasms. According forecast USA National Cancer Institute next 20 years every 2nd American man and third woman will get sick with cancer, therefore oncology should be considered main medical specialty. Molecular characterization tumors become routine, it provide an opportunity via screening detect precancerous abnormalities early forms cancer. Surgery mostly organsaving modality,...
The incidence of hepatocellular carcinoma (HCC) in Russia and worldwide is steadily increasing over time. majority HCC patients are diagnosed at a late stage the disease, which not suitable for potentially curative treatment methods. Before emergence new regimens, median overall survival this condition was just one year. Studying combinations immunotherapy targeted therapy has improved clinical outcomes compared to monotherapy with tyrosine kinase inhibitors, but regimens cannot be...